Neurodegenerative disorders are being fought with €28m

The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur will be able to advance its top drug, TT-P34, from candidate screening to clinical research, which will include a Phase Ib clinical trial for several neurodegenerative diseases. Aarhus University spin-off Teitur has created a platform of first-in-class cyclic peptides with a new mechanism that seems to maintain neuronal function.

The peptides may be used to help individuals with a variety of neurodegenerative illnesses. In rodent models of Huntington's disease, Parkinson's disease, and frontotemporal dementia, the lead drug candidate, TT-P34, which is given subcutaneously, has demonstrated strong, brain-specific effects. The three primary pathophysiological hallmarks of neurodegeneration—mitochondrial malfunction, lysosomal dysfunction, and loss of pro-survival signalling—are targeted by TT-P34, a drug that was created from the sortilin-related Vps10p domain containing receptor. In neurodegenerative disorders, TT-P34 supports neural cell survival by specifically restoring energy balance in brain cells, inducing clearing of harmful protein aggregates, and promoting neurotrophic effects.

Together with the new investors Industrifonden (Sweden), Innovestor's Life Science Fund (Finland), and P53 Invest, Sunstone Life Science Ventures and Sound Bioventures co-led the Series A funding. “The €28 million Series A investment further validates our vision for preserving neuronal function in the face of these devastating neurodegenerative disorders. The funding will allow us to take our first-in-class, lead drug candidate, TT-P34 from candidate selection into clinical development, while also advancing our novel pipeline of innovative, peptides,” stated Simon Mølgaard, Chief Executive Officer of Teitur Trophics.